Last updated on October 2018

Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1


Brief description of study

This Phase I dose escalation study will evaluate Procaspase Activating Compound-1 (PAC-1), a small molecule that activates procaspase -3 to caspase-3, resulting in apoptosis of cancer cells, in patients with advanced malignancies. PAC-1 is taken orally on days 1-21 of a 28-day cycle. The maximum tolerated dose (MTD) of PAC-1 (5 dose levels) will be determined using a modified-Fibonacci dose-escalation 3+3 design. Treatment continues until disease progression, unacceptable toxicity, physician discretion, or patient refusal.

Clinical Study Identifier: NCT02355535

Contact Investigators or Research Sites near you

Start Over

Oana Danciu, MD

University of Illinois at Chicago
Chicago, IL United States
  Connect »

Matthias Holdhoff, MD, PhD

Johns Hopkins Kimmel Cancer Center
Baltimore, MD United States
  Connect »

Richard Peterson, MD

Regions Hospital
Saint Paul, MN United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.